Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03654755 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Asana BioSciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT03654755 is a Phase 2 study that was terminated before completion, run by Asana BioSciences. The registered enrollment target is 162 participants.
The verdict
NCT03654755, a Phase 2 study, was terminated before completion, sponsored by Asana BioSciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
This is a randomized open label study to evaluate the long term safety of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
Interventions
- DRUG ASN002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2018-09-29 |
| Est. Completion | 2019-10-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03654755
The ClinicalTrials.gov registry entry for NCT03654755 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Asana BioSciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASN002 is the first listed.
NCT03654755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03654755 about?
NCT03654755 is a clinical study titled "Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis". This is a randomized open label study to evaluate the long term safety of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
What is the current status of trial NCT03654755?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2018-09-29. Estimated completion is 2019-10-29.
What interventions are being tested in trial NCT03654755?
The interventions under investigation include: ASN002 (DRUG).
Who is sponsoring clinical trial NCT03654755?
This trial is sponsored by Asana BioSciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.